CN107847609A - 用于治疗疾病的缀合物 - Google Patents

用于治疗疾病的缀合物 Download PDF

Info

Publication number
CN107847609A
CN107847609A CN201580079950.0A CN201580079950A CN107847609A CN 107847609 A CN107847609 A CN 107847609A CN 201580079950 A CN201580079950 A CN 201580079950A CN 107847609 A CN107847609 A CN 107847609A
Authority
CN
China
Prior art keywords
alkyl
alkenyl
alkynyl
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580079950.0A
Other languages
English (en)
Chinese (zh)
Inventor
I.R.弗拉霍夫
C.P.利蒙
L.齐
Y.王
K.Y.王
A.E.费尔滕
N.邹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of CN107847609A publication Critical patent/CN107847609A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201580079950.0A 2015-03-13 2015-03-13 用于治疗疾病的缀合物 Pending CN107847609A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/020397 WO2016148674A1 (en) 2015-03-13 2015-03-13 Conjugates for treating diseases

Publications (1)

Publication Number Publication Date
CN107847609A true CN107847609A (zh) 2018-03-27

Family

ID=56920017

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580079950.0A Pending CN107847609A (zh) 2015-03-13 2015-03-13 用于治疗疾病的缀合物

Country Status (6)

Country Link
US (2) US10624972B2 (https=)
EP (1) EP3268046A4 (https=)
JP (1) JP6676650B2 (https=)
CN (1) CN107847609A (https=)
CA (1) CA2979527A1 (https=)
WO (1) WO2016148674A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170266303A1 (en) * 2014-11-25 2017-09-21 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
JP6676650B2 (ja) 2015-03-13 2020-04-08 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 疾患を処置するためのコンジュゲート
US20200323991A1 (en) * 2016-03-29 2020-10-15 Endocyte, Inc. Pbd conjugates for treating diseases
WO2017205661A1 (en) * 2016-05-25 2017-11-30 Purdue Research Foundation Method of treating cancer by targeting myeloid-derived suppressor cells
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2021137646A1 (ko) 2019-12-31 2021-07-08 주식회사 레고켐바이오사이언스 피롤로벤조디아제핀 유도체 및 이의 리간드-링커 접합체

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548505B1 (en) * 1995-07-28 2003-04-15 Peter Maccallum Cancer Institute Radioprotectors
US20060019911A1 (en) * 1999-08-09 2006-01-26 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
CN101287500A (zh) * 2005-08-19 2008-10-15 恩多塞特公司 多药物配体缀合物
US20100074863A1 (en) * 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
CA2825919A1 (en) * 2011-02-15 2012-08-23 Immunogen, Inc. Methods of preparation of conjugates
CN102933236A (zh) * 2010-04-15 2013-02-13 斯皮罗根发展有限公司 吡咯并苯二氮卓类及其结合物
US20130267522A1 (en) * 2012-03-01 2013-10-10 Endocyte, Inc. Methods for treating cancer
WO2014062697A2 (en) * 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255789A (ja) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体，その製造法および抗腫瘍剤
CA2044590A1 (en) 1989-11-13 1991-05-14 Marc D. Better Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1992003569A1 (en) 1990-08-29 1992-03-05 Centre Hospitalier Regional De Nantes Protein polyligands joined to a stable protein core
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
JP4813712B2 (ja) * 1999-08-09 2011-11-09 ザ ジェネラル ホスピタル コーポレーション 薬物−担体複合体およびその使用方法
DK1592457T3 (da) 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
AU2006279304A1 (en) * 2005-08-19 2007-02-22 Endocyte, Inc. Multi-drug ligand conjugates
WO2008098368A1 (en) 2007-02-16 2008-08-21 Boehringer Ingelheim International Gmbh Inhibitors of hepatitis c ns3 protease
BRPI0812970A2 (pt) * 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
AU2009293140A1 (en) 2008-09-17 2010-03-25 Endocyte, Inc. Folate receptor binding conjugates of antifolates
CA2799391A1 (en) 2010-05-19 2011-12-04 Endocyte, Inc. Improved process for a folate-targeted agent
BR112015011118B1 (pt) * 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
US10131682B2 (en) * 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
LT3191135T (lt) 2014-09-12 2020-11-25 Genentech, Inc. Anti-her2 antikūnai ir imunokonjugatai
US20170266303A1 (en) 2014-11-25 2017-09-21 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
JP6676650B2 (ja) 2015-03-13 2020-04-08 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 疾患を処置するためのコンジュゲート
US20200323991A1 (en) 2016-03-29 2020-10-15 Endocyte, Inc. Pbd conjugates for treating diseases

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548505B1 (en) * 1995-07-28 2003-04-15 Peter Maccallum Cancer Institute Radioprotectors
US20060019911A1 (en) * 1999-08-09 2006-01-26 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
CN101287500A (zh) * 2005-08-19 2008-10-15 恩多塞特公司 多药物配体缀合物
US20100074863A1 (en) * 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
CN102933236A (zh) * 2010-04-15 2013-02-13 斯皮罗根发展有限公司 吡咯并苯二氮卓类及其结合物
CA2825919A1 (en) * 2011-02-15 2012-08-23 Immunogen, Inc. Methods of preparation of conjugates
US20130267522A1 (en) * 2012-03-01 2013-10-10 Endocyte, Inc. Methods for treating cancer
WO2014062697A2 (en) * 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUNJAN TYAGI等: "Binding of an indole alkaloid, vinblastine to double stranded DNA:A spectroscopic insight in to nature and strength of interaction", 《JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY》 *
IONTCHO R. VLAHOV等: "Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Also Published As

Publication number Publication date
WO2016148674A1 (en) 2016-09-22
JP6676650B2 (ja) 2020-04-08
EP3268046A4 (en) 2018-11-21
EP3268046A1 (en) 2018-01-17
US10624972B2 (en) 2020-04-21
CA2979527A1 (en) 2016-09-22
US20200289659A1 (en) 2020-09-17
US20180228914A1 (en) 2018-08-16
JP2018509424A (ja) 2018-04-05

Similar Documents

Publication Publication Date Title
CN110357889B (zh) 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
US20200289659A1 (en) Conjugates for treating diseases
JP2023021283A (ja) シリコン系複合体
JP2025114615A (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
WO2021205391A1 (zh) 靶向蛋白酶降解(ted)平台
RS59056B1 (sr) Derivati benzimidazola kao inhibitori bromodomena
CN114302744B (zh) 作为治疗剂的微管靶向剂的肽缀合物
US9527863B2 (en) Thieno-indole moieties and methods of treating using the same
US20200323991A1 (en) Pbd conjugates for treating diseases
CN120225225A (zh) 去泛素化酶靶向性嵌合体及相关方法
WO2016168471A1 (en) Dual disulfide drug conjugates
WO2016089879A1 (en) Conjugates of garftase inhibitors
EP2836493A1 (en) Functionalized thieno-indole derivatives for the treatment of cancer
US20230416331A1 (en) Peptide conjugates of peptidic tubulin inhibitors as therapeutics
CN119278034A (zh) 选择性组蛋白去乙酰化酶8(hdac8)降解剂和其使用方法
US20160303251A1 (en) Conjugates of garftase inhibitors
JP2021006550A (ja) 炎症の治療のための抗葉酸剤結合体
CN114390924A (zh) 用于蛋白质降解的化合物、组合物和方法
US20180125992A1 (en) Drug delivery conjugates of tertiary amine containing drugs
WO2023056981A1 (zh) 靶向蛋白酶降解(ted)平台
JP2020117509A (ja) 疾患を処置するためのコンジュゲート
WO2000041689A1 (en) Telomerase inhibitors
US10266547B2 (en) Thieno[2,3-e]indole derivatives as new antitumor agents
EA051761B1 (ru) Пептидные конъюгаты агентов, нацеленных на микротрубочки, в качестве терапевтических средств

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180327